No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design
Inflammation plays a pivotal role in the pathophysiology of cardiovascular disease, (CVD) and leukotrienes may play a role in atherogenesis. Statins reduce mortality from CVD by reducing LDL cholesterol and potentially by other (pleiotropic) mechanisms. The aim of this study was to investigate if at...
Gespeichert in:
| Veröffentlicht in: | Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 2012-12, Vol.87 (6), p.185-188 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 188 |
|---|---|
| container_issue | 6 |
| container_start_page | 185 |
| container_title | Prostaglandins, leukotrienes and essential fatty acids |
| container_volume | 87 |
| creator | Lysgaard, C Nielsen, M S Christensen, J H Lundbye-Christensen, S Riahi, S Schmidt, E B |
| description | Inflammation plays a pivotal role in the pathophysiology of cardiovascular disease, (CVD) and leukotrienes may play a role in atherogenesis. Statins reduce mortality from CVD by reducing LDL cholesterol and potentially by other (pleiotropic) mechanisms. The aim of this study was to investigate if atorvastatin exerts an anti-inflammatory effect by reducing leukotriene B₄ (LTB₄) formation from stimulated neutrophils in patients treated with coronary artery bypass grafting. The study was a randomized, placebo-controlled, double-blinded crossover study. Patients (n=80) were allocated to 80 mg atorvastatin or placebo for 6 weeks before crossing over to the opposite treatment for another 6 weeks. There was no significant correlation between baseline LDL cholesterol levels on formation of LTB₄, and atorvastatin had no effect on LTB₄ formation. Hence, this study does not support any effect of atorvastatin on LTB₄ formation as part of the explanation for its beneficial effect on CVD. |
| doi_str_mv | 10.1016/j.plefa.2012.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1285095929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1222235272</sourcerecordid><originalsourceid>FETCH-LOGICAL-p159t-65df3940bb0e6f80667c4749a19df896ec672a07fa40f2eb6b43c3bda63ae2363</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxi0EotvCEyAhH7kk-E_iJNyggoJUwQXOKzse77o4nmA7RcsR8YK8Ak-CpZY7cxnNfL_5NJoh5BlnLWdcvbxp1wBOt4Jx0bKpZax7QHa8l6IRo5APyY5NvWikGMYzcp7zDWNMcN49JmdCMiW5Gnfk90ek4BzMhaKjR384NhYzUF0w3epcdPGRYqQBtq9YkocI9M2fn7-ow7RUsUou4UIjbCXhevQh0zqxVgliybQk0AUs_e7Lkc6YMOp0oua06pxp3tIB0ukV1TTpaHHxPyq6Bj2DwWbGWC1DqC2LmwnQmOCjrWXdQ4c7S03nhDnjLSRqIftDfEIeOR0yPL3PF-TLu7efL98315-uPly-vm5W3k-lUb11cuqYMQyUG5lSw9wN3aT5ZN04KZjVIDQbnO6YE2CU6eQsjdVKahBSyQvy4s53Tfhtg1z2i88zhKAj4Jb3XIx9fcAkpv9Aa8heDKKiz-_RzSxg92vyS73Y_t_H5F9f-aCC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1222235272</pqid></control><display><type>article</type><title>No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lysgaard, C ; Nielsen, M S ; Christensen, J H ; Lundbye-Christensen, S ; Riahi, S ; Schmidt, E B</creator><creatorcontrib>Lysgaard, C ; Nielsen, M S ; Christensen, J H ; Lundbye-Christensen, S ; Riahi, S ; Schmidt, E B</creatorcontrib><description>Inflammation plays a pivotal role in the pathophysiology of cardiovascular disease, (CVD) and leukotrienes may play a role in atherogenesis. Statins reduce mortality from CVD by reducing LDL cholesterol and potentially by other (pleiotropic) mechanisms. The aim of this study was to investigate if atorvastatin exerts an anti-inflammatory effect by reducing leukotriene B₄ (LTB₄) formation from stimulated neutrophils in patients treated with coronary artery bypass grafting. The study was a randomized, placebo-controlled, double-blinded crossover study. Patients (n=80) were allocated to 80 mg atorvastatin or placebo for 6 weeks before crossing over to the opposite treatment for another 6 weeks. There was no significant correlation between baseline LDL cholesterol levels on formation of LTB₄, and atorvastatin had no effect on LTB₄ formation. Hence, this study does not support any effect of atorvastatin on LTB₄ formation as part of the explanation for its beneficial effect on CVD.</description><identifier>ISSN: 0952-3278</identifier><identifier>EISSN: 1532-2823</identifier><identifier>DOI: 10.1016/j.plefa.2012.09.004</identifier><identifier>PMID: 23063168</identifier><language>eng</language><publisher>Scotland</publisher><subject>Aged ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Atherogenesis ; Atorvastatin ; Atorvastatin Calcium ; Calcimycin - pharmacology ; Calcium Ionophores - pharmacology ; Cardiovascular diseases ; Cholesterol ; Cholesterol, LDL - blood ; Clinical trials ; Combined Modality Therapy ; coronary artery ; Coronary Artery Bypass ; Coronary Disease - drug therapy ; Coronary Disease - immunology ; Coronary Disease - metabolism ; Coronary Disease - surgery ; Cross-Over Studies ; Double-Blind Method ; Fatty acids ; Female ; Grafting ; Heptanoic Acids - administration & dosage ; Heptanoic Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - etiology ; Hypercholesterolemia - prevention & control ; Inflammation ; Leukocytes (neutrophilic) ; Leukotriene B4 ; Leukotriene B4 - metabolism ; Lipoproteins (low density) ; Male ; Middle Aged ; Mortality ; Neutrophil Activation - drug effects ; Neutrophils - drug effects ; Neutrophils - immunology ; Neutrophils - metabolism ; Prostaglandins ; Pyrroles - administration & dosage ; Pyrroles - therapeutic use ; statins ; Surgery</subject><ispartof>Prostaglandins, leukotrienes and essential fatty acids, 2012-12, Vol.87 (6), p.185-188</ispartof><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23063168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lysgaard, C</creatorcontrib><creatorcontrib>Nielsen, M S</creatorcontrib><creatorcontrib>Christensen, J H</creatorcontrib><creatorcontrib>Lundbye-Christensen, S</creatorcontrib><creatorcontrib>Riahi, S</creatorcontrib><creatorcontrib>Schmidt, E B</creatorcontrib><title>No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design</title><title>Prostaglandins, leukotrienes and essential fatty acids</title><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><description>Inflammation plays a pivotal role in the pathophysiology of cardiovascular disease, (CVD) and leukotrienes may play a role in atherogenesis. Statins reduce mortality from CVD by reducing LDL cholesterol and potentially by other (pleiotropic) mechanisms. The aim of this study was to investigate if atorvastatin exerts an anti-inflammatory effect by reducing leukotriene B₄ (LTB₄) formation from stimulated neutrophils in patients treated with coronary artery bypass grafting. The study was a randomized, placebo-controlled, double-blinded crossover study. Patients (n=80) were allocated to 80 mg atorvastatin or placebo for 6 weeks before crossing over to the opposite treatment for another 6 weeks. There was no significant correlation between baseline LDL cholesterol levels on formation of LTB₄, and atorvastatin had no effect on LTB₄ formation. Hence, this study does not support any effect of atorvastatin on LTB₄ formation as part of the explanation for its beneficial effect on CVD.</description><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Atherogenesis</subject><subject>Atorvastatin</subject><subject>Atorvastatin Calcium</subject><subject>Calcimycin - pharmacology</subject><subject>Calcium Ionophores - pharmacology</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Cholesterol, LDL - blood</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>coronary artery</subject><subject>Coronary Artery Bypass</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - immunology</subject><subject>Coronary Disease - metabolism</subject><subject>Coronary Disease - surgery</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Fatty acids</subject><subject>Female</subject><subject>Grafting</subject><subject>Heptanoic Acids - administration & dosage</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypercholesterolemia - etiology</subject><subject>Hypercholesterolemia - prevention & control</subject><subject>Inflammation</subject><subject>Leukocytes (neutrophilic)</subject><subject>Leukotriene B4</subject><subject>Leukotriene B4 - metabolism</subject><subject>Lipoproteins (low density)</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Neutrophil Activation - drug effects</subject><subject>Neutrophils - drug effects</subject><subject>Neutrophils - immunology</subject><subject>Neutrophils - metabolism</subject><subject>Prostaglandins</subject><subject>Pyrroles - administration & dosage</subject><subject>Pyrroles - therapeutic use</subject><subject>statins</subject><subject>Surgery</subject><issn>0952-3278</issn><issn>1532-2823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQxi0EotvCEyAhH7kk-E_iJNyggoJUwQXOKzse77o4nmA7RcsR8YK8Ak-CpZY7cxnNfL_5NJoh5BlnLWdcvbxp1wBOt4Jx0bKpZax7QHa8l6IRo5APyY5NvWikGMYzcp7zDWNMcN49JmdCMiW5Gnfk90ek4BzMhaKjR384NhYzUF0w3epcdPGRYqQBtq9YkocI9M2fn7-ow7RUsUou4UIjbCXhevQh0zqxVgliybQk0AUs_e7Lkc6YMOp0oua06pxp3tIB0ukV1TTpaHHxPyq6Bj2DwWbGWC1DqC2LmwnQmOCjrWXdQ4c7S03nhDnjLSRqIftDfEIeOR0yPL3PF-TLu7efL98315-uPly-vm5W3k-lUb11cuqYMQyUG5lSw9wN3aT5ZN04KZjVIDQbnO6YE2CU6eQsjdVKahBSyQvy4s53Tfhtg1z2i88zhKAj4Jb3XIx9fcAkpv9Aa8heDKKiz-_RzSxg92vyS73Y_t_H5F9f-aCC</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Lysgaard, C</creator><creator>Nielsen, M S</creator><creator>Christensen, J H</creator><creator>Lundbye-Christensen, S</creator><creator>Riahi, S</creator><creator>Schmidt, E B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201212</creationdate><title>No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design</title><author>Lysgaard, C ; Nielsen, M S ; Christensen, J H ; Lundbye-Christensen, S ; Riahi, S ; Schmidt, E B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p159t-65df3940bb0e6f80667c4749a19df896ec672a07fa40f2eb6b43c3bda63ae2363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Atherogenesis</topic><topic>Atorvastatin</topic><topic>Atorvastatin Calcium</topic><topic>Calcimycin - pharmacology</topic><topic>Calcium Ionophores - pharmacology</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Cholesterol, LDL - blood</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>coronary artery</topic><topic>Coronary Artery Bypass</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - immunology</topic><topic>Coronary Disease - metabolism</topic><topic>Coronary Disease - surgery</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Fatty acids</topic><topic>Female</topic><topic>Grafting</topic><topic>Heptanoic Acids - administration & dosage</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypercholesterolemia - etiology</topic><topic>Hypercholesterolemia - prevention & control</topic><topic>Inflammation</topic><topic>Leukocytes (neutrophilic)</topic><topic>Leukotriene B4</topic><topic>Leukotriene B4 - metabolism</topic><topic>Lipoproteins (low density)</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Neutrophil Activation - drug effects</topic><topic>Neutrophils - drug effects</topic><topic>Neutrophils - immunology</topic><topic>Neutrophils - metabolism</topic><topic>Prostaglandins</topic><topic>Pyrroles - administration & dosage</topic><topic>Pyrroles - therapeutic use</topic><topic>statins</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lysgaard, C</creatorcontrib><creatorcontrib>Nielsen, M S</creatorcontrib><creatorcontrib>Christensen, J H</creatorcontrib><creatorcontrib>Lundbye-Christensen, S</creatorcontrib><creatorcontrib>Riahi, S</creatorcontrib><creatorcontrib>Schmidt, E B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lysgaard, C</au><au>Nielsen, M S</au><au>Christensen, J H</au><au>Lundbye-Christensen, S</au><au>Riahi, S</au><au>Schmidt, E B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design</atitle><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><date>2012-12</date><risdate>2012</risdate><volume>87</volume><issue>6</issue><spage>185</spage><epage>188</epage><pages>185-188</pages><issn>0952-3278</issn><eissn>1532-2823</eissn><abstract>Inflammation plays a pivotal role in the pathophysiology of cardiovascular disease, (CVD) and leukotrienes may play a role in atherogenesis. Statins reduce mortality from CVD by reducing LDL cholesterol and potentially by other (pleiotropic) mechanisms. The aim of this study was to investigate if atorvastatin exerts an anti-inflammatory effect by reducing leukotriene B₄ (LTB₄) formation from stimulated neutrophils in patients treated with coronary artery bypass grafting. The study was a randomized, placebo-controlled, double-blinded crossover study. Patients (n=80) were allocated to 80 mg atorvastatin or placebo for 6 weeks before crossing over to the opposite treatment for another 6 weeks. There was no significant correlation between baseline LDL cholesterol levels on formation of LTB₄, and atorvastatin had no effect on LTB₄ formation. Hence, this study does not support any effect of atorvastatin on LTB₄ formation as part of the explanation for its beneficial effect on CVD.</abstract><cop>Scotland</cop><pmid>23063168</pmid><doi>10.1016/j.plefa.2012.09.004</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-3278 |
| ispartof | Prostaglandins, leukotrienes and essential fatty acids, 2012-12, Vol.87 (6), p.185-188 |
| issn | 0952-3278 1532-2823 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1285095929 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Atherogenesis Atorvastatin Atorvastatin Calcium Calcimycin - pharmacology Calcium Ionophores - pharmacology Cardiovascular diseases Cholesterol Cholesterol, LDL - blood Clinical trials Combined Modality Therapy coronary artery Coronary Artery Bypass Coronary Disease - drug therapy Coronary Disease - immunology Coronary Disease - metabolism Coronary Disease - surgery Cross-Over Studies Double-Blind Method Fatty acids Female Grafting Heptanoic Acids - administration & dosage Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - etiology Hypercholesterolemia - prevention & control Inflammation Leukocytes (neutrophilic) Leukotriene B4 Leukotriene B4 - metabolism Lipoproteins (low density) Male Middle Aged Mortality Neutrophil Activation - drug effects Neutrophils - drug effects Neutrophils - immunology Neutrophils - metabolism Prostaglandins Pyrroles - administration & dosage Pyrroles - therapeutic use statins Surgery |
| title | No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A55%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20effect%20of%20high-dose%20atorvastatin%20on%20leukotriene%20B%E2%82%84%20formation%20from%20neutrophils%20in%20patients%20treated%20with%20coronary%20bypass%20surgery:%20a%20randomized%20placebo-controlled%20double-blinded%20trial%20with%20a%20crossover%20design&rft.jtitle=Prostaglandins,%20leukotrienes%20and%20essential%20fatty%20acids&rft.au=Lysgaard,%20C&rft.date=2012-12&rft.volume=87&rft.issue=6&rft.spage=185&rft.epage=188&rft.pages=185-188&rft.issn=0952-3278&rft.eissn=1532-2823&rft_id=info:doi/10.1016/j.plefa.2012.09.004&rft_dat=%3Cproquest_pubme%3E1222235272%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1222235272&rft_id=info:pmid/23063168&rfr_iscdi=true |